In short
Taste Radio Episode Summary
Episode Title
Bonus Content - Ozempic's Effect on Bev-Alc Consumption
Episode Description In this episode, analysts Nadine Sarwat and Trevor Stirling from Bernstein Autonomous share their insights on how Ozempic and other diabetes drugs may affect alcoholic beverage consumption.
---
Key Participants
- Hosts: Justin Kendall, Jess Infante, Zoe Licata
- Guests: Nadine Sarwat, Trevor Stirling
---
Introduction
- Context: The episode begins with the hosts discussing the upcoming Brewbound Live Business Conference set for December 6th-7th in Marina del Rey, California.
- Personal updates: The hosts share personal news, including family updates that add a light-hearted tone to the introduction.
Brewbound Live Conference
- Networking Opportunities: The hosts highlight the diverse lineup of speakers and the chance for attendees to network, emphasizing the potential for productive conversations and collaborations.
- Keynote Speaker: Adam Bankovich, new CEO of Reingeist, will deliver the keynote address.
Industry News Highlights
- Reingeist Leadership Changes:
- Adam Bankovich is now the full-time CEO after an interim period, marking a significant leadership transition.
- The company is focusing on new strategies as they reach their decade mark.
- Creature Comforts Union Vote:
- The vote fell short for the union organized by the Brewers Union of Georgia (BUG) amid ongoing discussions about labor organization in the craft beer industry.
- Non-Alcoholic Beer Trends:
- Insights from Whole Foods representative Mary Giver indicate that shelf space for non-alcoholic beers is nearing its limit, which could affect market dynamics in the future.
Main Discussion
Ozempic's Impact on Alcohol Consumption Overview of Ozempic and GLP-1 Drugs
- Drug Purpose: Originally for diabetes, used for weight loss with side effects that may include reduced appetite for alcohol.
- Demographic Insights: Analysis shows that users tend to be overweight individuals, primarily female, and often from higher income brackets who may use it for lifestyle reasons.
Potential Impact on Alcohol Consumption
- Statistical Analysis:
- Current obesity rate in the U.S. is around 42%, which serves as the target demographic for this analysis.
- After considering various assumptions, the impact on alcohol volumes is predicted to be around -2% over a decade.
Celebrity Influence and Public Perception
- The conversation highlights how increased media attention and celebrity endorsements are heightening awareness and perceptions of Ozempic, potentially influencing broader consumer habits.
Consumer Behavior Insights
- Early anecdotal reports suggest varying degrees of alcohol consumption reduction among users, with a notable portion reporting less desire for alcoholic beverages.
Conclusions and Future Considerations
- Long-Term Effects: The analysts predict that while initial impacts may be limited, ongoing changes in consumer behavior and perceptions will continue to evolve, particularly as more data becomes available over the next 6-12 months.
- Industry Reaction: Companies in the alcoholic beverage space are currently calm but are monitoring the situation closely as investor anxiety grows.
---
Key Takeaways
- Ozempic and similar drugs may have a limited but measurable impact on alcoholic beverage consumption over time.
- There is a significant interest in understanding how these changes will affect different alcohol categories, with varying implications for beer, wine, and spirits.
- The conversation suggests that as consumer habits shift, the beverage industry must remain adaptable and responsive to emerging trends.
Closing Remarks
- The episode wraps up with appreciation for guest insights and a reminder for listeners to tune in for future episodes.
---
Contact Information
- Share thoughts or inquiries at ask@tasteradio.com.
- Sponsorship opportunities are available for interested parties.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:28Thanks for tuning into Taste Radio.
0:40Hello and welcome to the Rebound Podcast. I'm Justin Kendall. I'm Jess Infante. And I'm Zoe Licata. And this episode, as I plugged at the top, we are going to be talking about Ozempic, the weight loss drug and its potential effect on alcoholic beverage consumption. Joining us later in the show will be Nadine Sarwat and Trevor Sterling. You might know them as analysts with Bernstein. They've done extensive research on Ozempic and the potential effects on alcoholic beverage consumption. So we'll hear all about it with them and tell you what you should know. But first, let's plug the BrewBound Live Business Conference coming up December 6th and 7th in Marina del Rey, California.
1:26That's coming up pretty quick. We've got a great lineup coming together. I think it's one of the best lineups we've done. Yeah, I'm excited for Rebound Live. I booked my flight yesterday, but I actually booked two flights because my baby is coming. I can't promise she will be at the conference, but she will be in the area with my mom. That's very exciting. I also booked my flights this weekend. I think that means it's real. It's happening. We're actually going to be there. It's happening. Yeah. There are two ways to take my baby is coming. So like, I'm glad that it's she's coming with instead of, you know, she's not here yet, but she's going to be here.
2:06Yeah, we're not doing a live birth on stage. No, no. She she will be six months old at that time. Yeah. And mine will be two. Like the day that the show ends, she will have her second birthday. Oh, that's right. Great. That's right. Yeah. Enough of that. Let's talk about the things that are going to happen at Brewbound Live. And I will say that there's going to be a lot of networking, some with Jess's baby, maybe. And then, yeah. And, you know, people will probably be excited for that. They'll also be excited to hang out with a lot of our speakers. You know, we've got C-store buyers, we've got leaders from Rheingeist, Crowns and Hops, the National Black Brewers Association, the Brewers Association, Extra Mile Convenience Stores, Circle K, Stone Distributing, Breakthrough Beverage.
2:57We've got a whole lineup that is just you're not going to find a lineup like this anywhere else. No, no. It's diverse in terms of like age of presenters, ages of the companies involved, in terms of like angle of the industry, segments, geography. We've got some old favorites. We've got new faces. I'm pretty pumped. Yeah. And this is a chance to interact with a lot of these folks, network with them, set up meetings, you know, make new partnerships. One of the things that you two did was interview Schilling Cider about National Cider Month. And that program was largely born, I think, out of conversations that we had.
3:43that Schilling had with Mary Guyver from Whole Foods at Brewbound Live. Yeah, it was just one of many stories that we've heard. We're not making them up. They really are happening where there is productive networking happening at Brewbound Live and we are seeing things come about because of those conversations that happened there. So that was just the most recent one that we've heard of. And it's turned into a big program for both Whole Foods and for Schilling and for just all cideries who are involved with National Cider Month and doing some programming for it. So it was really cool. So set up some meetings.
4:19Join us in Marina Del Rey. You won't regret it. You can get tickets at brewboundlive.com. With that, let's get to the news of the week. And speaking of Brewbound Live, our keynote address will be delivered by new Ryan Geist CEO Adam Bankovich. And he'll be joined on stage a little bit later by Ryan Geist co-founder, Brian Goulding. But Reingeist announcing its leadership changes, a lot of promotions. Reingeist dropped the interim tag from Adam's title, and he is now the full-time CEO of the company. Yeah, we saw Adam get that interim tag earlier this year. And when we talked to both him and Brian at that time, they said, you know, we're being genuine about saying, you know, he's not just guaranteed this job.
5:06We're going to do a full search of who's going to be right as our next CEO. And it turned out that it really was Adam and he showed the right kind of leadership that they were looking for and was on the same base with everyone about this new focus approach that they're having going forward. So we also got to talk to them about some of their new strategies going into this coming year, which is another one of the reasons why they'll be kind of kicking off Brewbound Live for us is because they've reached this decade mark and they're trying to figure out what Reingeist looks like now and how to do that in the best, most productive way, both in terms of just physically what a company can do, but also in what's best for sales, what's best for morale, so many different aspects of the business.
5:57It's been really interesting to watch Reingeist mature and grow and evolve the past few years. Because two years ago, two plus years ago, Brian and his co-founder, Bob, decided to step down from being really in the nitty gritty of the day-to-day step and hire an external CEO to take over. And that person came from outside the industry and they were around for a little bit, but I think eventually they had decided to part ways as well. And that's a tough call when you're a founder and you decide, Hey, you know, I've got, I built this thing and I've gotten it to this point, but, but what we need is someone else to steer the ship.
6:35But that's a big choice to make. And I remember feeling so impressed with, with Brian and Bob that they knew that they didn't quite have like the skills to build and the skills to maintain at scale are very different. So, and I'm just so excited to see what Adam does with the role because, you know, he started with them last year as chief commercial officer, joined us at BrewBound Live on stage for a conversation about fourth category. And here he is. So it's really interesting to be able to watch all of these things happen. Yeah. One of the things that Bryant kept repeating in the most recent conversation we had with him was about getting out of your own way.
7:12And I think that part of that was that change away from the co-founders in such involved leadership roles was they acknowledged that they don't need to be as involved in some of those business-making decisions and can get away from some of that big craft entrepreneurial environment that can get a little extensive in innovation and other things sometimes. And so it's been this new theme for them. It's just getting out of your own way and figuring out what's best for the company overall. Perfect segue for what I was just gonna say, which is that in terms of getting out of your own way, like they told us that they're really kind of re-imagining, but kind of discontinuing the RG Bev's line, which was what Adam was joining us at BrewBound Live to talk about was their line of, you know, fruit forward malt beverages that like aren't quite F &Bs, but aren't quite beer and aren't quite cider.
8:05And I think they really listened to consumer feedback who said, hey, I remember the way that, you know, your bubbles used to be and why is bubbles different now? So one thing that they were doing in terms of getting out of their own way is to just going back to basics to something that worked, which you don't see too many companies innovate that quickly and kill the innovation product as quickly as they did because they just said, hey, this isn't working for us. So they got out of their own way. Yeah. They said that the consumer found it confusing that they didn't know what RG Bev's was. And so getting the Rheingeis name on Bubbles made a lot of sense.
8:44Yeah, there are going to be themes interwoven within that keynote address that are, you know, themes that are going to carry from 2023 on into 2024. And that's focus. And that's leadership change at the top of major craft breweries. And Zoe and I have tracked it all year long in your absence, Jess. And we've got a whole list. It reads like a giant scroll of leadership changes this year. And Adam represents some of that new blood that's coming in and taking over some of these roles. So very excited for him. Very excited also for everybody that got a promotion at Ryan guys. Cole Hackbarth is the new VP of brewery operations.
9:28Mark Fingoni has been promoted to VP of sales and Tracy Ireland has been promoted to VP of Marketing. Congrats to all of them. Awesome news for everybody. Good to see the company promoting from within and just paying off some longtime workers. Let's talk about something else that involves workers and culture, and that's at Creature Comforts. And the Brewers Union of Georgia, BUG as it's known as, they had a union vote at creature comforts and it fell short. Yeah, we've been waiting to see Bug even have this vote, let alone see a result for the majority of this year. They had been waiting for this result of this pre-election hearing that they had back in February to just be able to have an election vote.
10:21And they got the answer that the basically the allowance of being able to have this election in August. And so that election was held and had a majority vote, 32 against 21 in favor of the Creature Comforts union being recognized and being supported by BUG. So we have gotten statements directly from Creature Comforts as of this point, but we have been in contact with BUG and should have some more information from them soon. But Creature Comforts told us that BUG is fighting the results of it. So this might not be the end of this conversation. We might have more coming out of this, so stay tuned for that.
11:05But Creature Comforts told us in a statement shared with us that they were pleased but not surprised by the results and that there was a pretty large voter turnout. 90 % of eligible employees participated in the election. I think it was a bit of surprise just by the amount of vocalization there was around this vote happening. But stay tuned because there will certainly be more to come. One of the things about craft is that unions are surprisingly rare within it. We saw anchors, workers succeed at forming a union, and they were on the verge of another contract when Sapporo made the decision to cease operations at Anchor and liquidate the business.
11:51And we saw an effort at Surly fail. It came up, I believe, one vote short of being able to unionize there. And then the one example I think that we've seen, management recognize the union, is Fair State Collective in Minnesota as well. Yeah, and all of those three things have something in common that Bug did not. Those were all attempts to join existing organized labor forces. So in Minnesota, both breweries were trying to join the Unite Here Local 17. Unite Here is a hospitality workers union. At Anchor, they were part of the ILWU, the, I'm going to get this wrong, but International Longshoremen, which is a long, long established union that certainly has deep roots in San Francisco.
12:39But Bug was new and the workers were trying to create their own organization. And they were taking a page out of the playbook that worked so well at Amazon and Staten Island, but that didn't quite work out down in Georgia. But really hard to build your own, you know, labor organization from scratch. Yeah. And this was also plagued with some other internal issues and allegations of some of the leadership members being fired or other consequences because of their involvement with this. So just the trying to unionize alone, there's a lot going on there, but then also tackling any other things that might be happening in your workplace.
13:19It adds even more complications. Tough. All right, let's round out the news segment with a little bit of catch up coverage. I went to the Beer Institute meeting in Denver earlier this month. And one of the highlights for me was Danelle Cosmal's conversation with Mary Giver from Whole Foods and Matthew Crompton from CGA. And Mary's comments really stood out to me because we've seen a lot of folks try and get into the non-alcoholic beer space. And Mary is pretty much saying, look, we are near or very much at our limit of what we can take. We've got all the space that we can handle for non-alcoholic beer.
14:03and at this point it's supporting the brands that they already have who she said are some of their top brands period yeah which is super impressive but i mean i know we've seen recent comments oh on our own taste radio uh bill schufeldt told our colleague ray latif that he thinks not not beer could get to be 20 percent of the beer category and he's an optimist he's a very very big optimist and good on him. I don't know that I see that, but I think what we're seeing there kind of jives a little bit with what Mary's saying is that there's only so much room on shelves. Yeah. But NA brewers have one thing in their toolkit that they can play and that is DTC shipping.
14:53I think it's also a nice reminder for when, I mean, we've been talking about all year, looking at the data and non-alc has been one of the few segments within beer to record any sort of growth and so a lot of producers are starting to look at it we've heard a couple of announcements of some bigger players getting into non-alc this coming year but just because a segment is growing and scans doesn't mean there's actually more room for it or that that's going to continue or that everybody can play in that space so i think it's a little bit of a warning or a wake of call from Mary being like, hey, just we understand this segment is really important to us.
15:33It's really important to a lot of you, but don't get too ahead of yourselves there. There's only so much space we can really give you. One of the things that she also did say is she's not trying to dissuade suppliers from getting into this space. She did say there are other paths in. So if you want to do this as a seasonal or a one-off, there's an opportunity potentially there. But it's also one of those where it's like, look outside of IPA and lager, find your space. And maybe she brought up Oktoberfest or flavored hop waters or those spaces, which I think that would be a smart play for some folks.
16:16And it would be interesting to see that some brewers treat this as a seasonal product where it comes in first half of the year cycles back out. Or maybe you have a couple of seasonals, you know, one for dry January, one for sober October, who knows? And the other thing that she brought up, and I thought that this was really powerful, was in a room full of some of the leaders of the biggest beer companies in the United States. And she's telling them that, look, there is a diversity issue in this industry, but there are producers who are women and who are black, indigenous people of color who are rising up in the industry and they're doing it at a craft level.
17:03And those are voices that need to be heard. And I think that that was an important message to send to everybody in that room who looked a lot like me. I mean, if everybody in that room hasn't heard that before, then I would question many things about them. But yes, for sure, absolutely needs to be said. It needs to be said until people actually start taking that into serious consideration. Yeah. And I'll just read her quote real quick. There is a ton of energy around the fact that there is just a missing component of the human population in the U.S. that aren't represented in beer right now. And what a great time to finally have this dialogue and start to support those brands.
17:45And it's happening at a craft level. They haven't had the support at a larger level historically. So here comes this wave of producers who are demanding to be represented in retailers and on tap. And I'm so excited to be a part of that conversation. And there's more to it. You can read it all at brewbound.com. But the gist of this is a lot of the younger voices out there need to be heard, and they are critical to helping this category grow. It's not new news, but important message in that room. Yeah. And I think people may be more susceptible to hearing it now because there's been more large scale representation of some of these brands with the creation of like the National Black Brewers Association.
18:32There seems to be like there's just more brands in general that are out there trying to directly combat some of the statistics out there of just how well represented some people are and some demographics are and ownership of breweries and all those other things. So there are some things that are moving towards trying to actually take some actionable steps and not just keep talking and having the same data points every year. And so I think Mary is trying to point to that and be like, hey, these are some actual direct people that you can look at and try to support right now. Now's the time. If you haven't been doing anything, look, there's people out there.
19:13We're not just kind of making this up. Yeah, I mean, as beer is losing share to spirits and people are drinking less, it just makes sense to go find people who haven't traditionally been drinking beer and try to welcome them. All right, let's play another rounder tabbing out. And we've seen a lot of crossover beverages. Coca-Cola continues to get in this space. The next one up is Sprite and Absolute. It's going to be in Europe. We don't know when it's coming to the US, but are you here? Are you tabbing out buying another round of Absolute and Sprite? do we have a time machine to 20 years ago because that version of me yeah she's it yeah yeah i can't say i'm a big soda drinker but when i would have soda sprite was normally the one i would go with as a teenager or college student and like this 100 speaks to that version and that demographic, I think.
20:14I'll be interested to see if it translates. I have a hard time seeing a lot of these canned cocktails be adapted by consumers who are making their own just like makeshift mixer and spirit spaces. If they're switching to the canned versions, I don't know. I mean, it's worked for Jack Daniels and Coca-Cola with their Jack and Coke RTD. Sprite and Absolute feels a little bit more makeshift to me, but I don't know. We'll see if people are into converting to ready-made versions. I hate this word, but Jack and Coke is iconic. I feel like iconic is mostly overused and usually not applicable, but in this case, I think it applies.
21:02Sprite and vodka, I don't know. I'm sure I've had many of them in the past. I mean, it's convenient. You know, I think one thing that these RTDs do all have going on is that they're super convenient. And in some cases, it's not something you can make that easily. So like, look at like all of high noon, like you don't just have like, say watermelon juice kicking around. Yeah. It'd be easy to make like vodka, sparkling water, watermelon juice sounds tasty. and I would like one right now, but it's not realistic to have that much different kinds of juices hanging in your fridge in the quantities that you would have to buy them in the grocery store.
21:44So yeah, high noon. Great. Perfect. Very handy. Yeah. I think there, maybe this brings up the conversation that people might start having about like, how do you tow the line of convenience where it's almost going past that and you're not actually providing an added convenience? I feel like most people, if you're making a Sprite and Absolute, you care about your own quantity of each of those in your drink. The two easy things that you can pick up at most stores around. But like you said, like if you're looking for more flavors or more intricate cocktails, a canned version of that that's already made is so much easier.
22:18So I don't know if this is actually providing a more convenient option. It might be. We'll see. Are we fatigued on this? Is this losing its novelty of, you know, X big brand is now partnering with an alcoholic brand? Personally, yeah. Yeah. But and we pay much closer attention to this than any normal person does. Yep. Or should. So who knows? Yeah. Like the thing that I heard the most about from my friends was Jack and Coke. people were seem to be excited about that most other you know crossover rgd launches i don't think get that much traction yeah i think it depends on how big the base of those two brands like that consumer base is already and how excited they're going to be about having this i think with this brand the same as all the other brands that have come by there's going to be a lot of initial excitement and momentum possibly.
23:17I think we are past that being long lasting or sustaining because it's not novel anymore. Yeah, I think we're well past it. But I'm also way too close to this to know or have a good feeling for it. You know, so when you talk to your friends about Duncan, and they seem excited or something, I think that sort of, you know, raises a flag for me, but I don't know. Like at this point, it's like everything is BevAlk. If it's not already, it's going to be before too long. And then we're going to have to take a Zen pick. God, no. So let's get into that conversation with Nadine Sarwat and Trevor Sterling from Bernstein.
24:03All right, let's welcome our guests, analysts and leaders at financial services firm Bernstein Autonomous. We have Nadine Sarwat. Thanks for being here, Nadine. Thanks for having me. And we have Trevor Sterling. Thanks for being here, Trevor. Great to be with you. So in our space, in your space, there seems to be a lot of concern over the long-term effects of Ozempic and other GLP-1 diabetes and diet drugs and how that might affect alcoholic beverage consumption. We've seen stories in the New York Times and Bloomberg. In your estimation, how much of this concern over these drugs impact on alcoholic beverage consumption is either founded or maybe overstated at this point?
24:48Well, that's a billion dollar question. So I think it'd be actually helpful to answer your question, to take a step back and consider how did we get here? Because that's going to help us understand where could we go forward. So if we compare, you know, we now have the set of drugs, GLP-1s. If we look back, historically used perhaps for diabetes, that's where the origin was. And the side effect was weight loss. And so now we are seeing these drugs used for either people who are obese or overweight as a way to kickstart that weight loss process. And ideally, you're doing that with the help of a physician and a support network.
25:25The side effect of that is, in addition to losing weight, you lose the appetite for alcohol for some people. Now, this is where we start to get into the questioning. What does that look like? Is it the same for everybody? And that's why that's coming up so much. So if we look at how that's going to play out, we actually did a little piece of analysis. I'm going to consult some numbers to get those right here. So if we start with the, you know, how big is the population in America that's obese? Well, we have it at about 42 percent. So that's your core demographic to start with when we're starting to understand what the impact is going to be on alcohol.
26:02Then we get into the line of making assumptions to understand, is this going to actually have an impact? So you have to make assumptions, for example, of those 42 % of people who are obese, how many have access to these drugs, either through insurance or are willing to pay for it themselves. You then have to make assumptions about how long they are willing to stay on it. Sometimes we're seeing data that people last on 12 months. Others are saying they want to be on this for the rest of their lives. And so that's another assumption. After we have that, we have to go one layer deeper. Of the people who are on the drugs, how much are they actually cutting their alcohol?
26:38And then of that cut, volume-wise, it's not just frequency, but volume, how is that impacting? So when we go through all of the layers and we put what we consider are some realistic worst-case assumptions, we get to an impact of about minus 2 % on volumes over the span of 10 years. and now that's per capita consumption i should actually add or about 0.2 to 0.3 per year after you go through all of the layers so this might not be the you know disaster that many people are expecting but there are clearly a huge number of assumptions that we're making there okay anything to add yeah i think the first thing to say is glp1s aren't new they didn't come yesterday they've been using the treatment of diabetes for quite a few years now.
27:28And it's really only the last month or two that the feeding frenzy has sprung up about the threat to the alcohol industry. So I think the first thing you say, until a few months ago, nobody was raising this as an issue. I think that gives you some sense of there's a lot of people out there who have been treated for diabetes with GLP-1s, and we haven't seen dramatic reductions in alcohol consumption. So I think it's absolutely certain to say some people, if they take these drugs for weight loss, do have reduced appetite for alcohol. But all the maths that we've done so far says the impact on the total alcohol industry is likely to be relatively limited.
28:06What's different now? Why is it that at this point, if they've been around for this long, that over this last month or so that we're hearing more about it, sing more about it? I think the first thing is celebrities. We have a lot of celebrities out there talking about it. It's a joke at the Oscars. So the whole awareness of the category has become much greater. I think also probably all of us know somebody who's tried Ozympic or Wigofi, and we all know some person who has said, you know what, I don't want to drink as much as I used to. So I think that's part of it. I think there is also the whole category of drugs seem to be having more and more benefits.
28:47So there are clinical studies out there looking kind of help on heart disease, clinical studies out there on addiction. It acts in two ways. One is to make you feel fuller. So you don't need to drink or sort of eat and drink as much as you would do. But the second one is it interferes with the receptors in your brain and the whole dopamine. So for instance, if you smoke, the nicotine receptors in your brain that give you the nicotine rush, the dopamine rush comes with nicotine, potentially these drugs could interfere with those receptors. So they could reduce your appetite to smoke as well. So it's a very uncertain science at the moment about how these things are going to work.
Read the full transcript
29:29And when you get vacuums, people fill it with assumptions. And it's nearly always bad assumptions. People don't fill it with good assumptions. And one thing I'll add to what Trevor said is what has changed, Justin, was your question. We've always had drugs around that physicians could prescribe for those with alcohol use disorder that would curb the desire to drink alcohol. So from that perspective, that side effect in and of itself of these GLP-1s is not new. So when we're thinking about how do we frame this for alcohol, well, we have to then think about the concentration of where is alcohol most likely to be consumed and how does that relate to GLP-1s.
30:08So if we do a sort of really broad scale scan of academic data, broadly in developed markets, we find that about 20 % of the adult population drinks anywhere between 65 % and 90 % of alcohol volumes. Now, remember, that's the population. So if I were to do that number for the drinking population, which we know is about, in America, two-thirds, that would not be as sort of concentrated there, be a bit more spread out. But suffice to say, then the question becomes when we're trying to understand what's new here with these GLP-1 drugs, how is the population of people who consume GLP-1 drugs or are most likely to overlap with that very highly concentrated area of sometimes what we'll coin, you know, power consumers of that category?
30:57And then we have two questions to ask. And this comes back, Justin, to, you know, what's new here? The first is, are people who, let's say, are more likely to be obese or overweight and therefore more likely to consume these drugs, are they also more likely to be those power users of alcohol products? Data so far is pretty mixed. You know, I know people that are the most athletic and they drink more than me. And then I'll probably also know people on the other end of the spectrum. And academic studies are sort of not in agreement there. So that in and of itself would lend itself to say, look, maybe we shouldn't worry so much about GLP-1's impact on alcohol, at least versus other categories.
31:35The second is, does GLP-1's presence, as Trevor said, with celebrities actually lead to them being more mainstream, more sourcerally acceptable than these other drugs that we've had for people who did want to curtail their alcohol consumption? That is still a big question mark, but that's how to think about what's changed now versus two years ago. So I'm glad you guys brought up the celebrity aspect here because, you know, the chatter about Ozempic and similar drugs in popular culture, at least in what I receive, because, you know, I think we all kind of get our own version of what's in the ether based on, you know, all the algorithms.
32:10But I mean, it tends to surround famous and almost famous women, which is not to offend any of the Real Housewives, but I think they're a big part of this. So what do non-celebrity users of this drug look like? And then I don't know that we can get there, but based on the demographics of those people, can we make any deductions about their prior alcohol of choice? So I think what I'm trying to ask here, is there a chance that this is more of a problem for, say, wine than beer? What we know so far is that consumers who are using the drug for weight loss reasons tend to skew heavily female. And we also know that in general, women drink less alcohol than men.
32:52Women are less likely to drink alcohol than men. So I think that's one thing we can say. When you get on to income, there's probably two things. I think there's people who are put on the drug for really valid clinical reasons. And we also know that obesity, clinical obesity, tends to skew lower income. But then there are people who are going on to the drug for lifestyle reasons. And they tend to be higher income because if you're paying for it yourself, and these things are very expensive. So we're almost getting a barbell distribution, but definitely skews more towards female at the moment. And definitely then probably this mixture of very affluent and not so affluent people.
33:29For beer, that's probably relatively good news. Because if you like, the classic Joe six pack is not in the target market here, and probably will be the last of the people to adopt these drugs. But you're absolutely right, at the moment, this is all completely anecdotal and there are very few facts out there but i have to say i'm probably more worried if i was making chardonnay than light beer and jessica you said that you said anecdote i have a good one for you i went and got my haircut this weekend and was eavesdropping on the conversation of the people sitting right next to me and the hairdresser was telling their client that his mom is actually on now glp1s and was raving about how much weight she had lost over a month period unless his mom is a celebrity that I'm unaware of.
34:15I suspect this is a very standard, someone wants to lose weight and is using this as a way to kickstart that process. So down to Trevor's description to a T. Wow. So I was just pregnant. And during that time I had gestational diabetes, which is something completely different. It comes to your placenta and all of that. You know, it goes away as soon as you have the baby, which it did, thank goodness. But I must've just Googled. I don't know if it's because of me Googling the gestational diabetes, what can I eat? What do I need to know? Or just being a 38 year old woman, but I get bombarded with ads for Ozempic on every social app, everywhere I go, all I see is just ads for Ozempic all the time.
34:55So, I mean, Zoe, you're nodding. So I assume maybe you are also getting this. So maybe it's not the gestational diabetes. No, I think it's definitely, I mean, I would concur that we've just personally have observed similar things of just it's being leaning a lot towards women towards that like right around Jess's age like it and I'm also seeing in my 20s seeing them everywhere so it's definitely in the ether kind of in all spaces that you're looking I'm curious we've heard I mean there's been I know this is a drug that is used for actual medical reasons, but because it has that kind of social aspect to it.
35:35We've seen other diets and weight loss fads happen over the years. How does this one and its effect on alcohol consumption differ or does it not versus previous ones? What makes this one a little bit different? Well, that's very good. But I think, remember, the first thing is it didn't cost you anything to go on the Atkins diet. If this is going to cost you$1 ,500 a month, that's very, very different. and so i think that you've got this thing of the where it's being used for a real clinical and you want your insurance company to pay for it they're going to ask you to go through all sorts of hoops first before they'll pay that for you have you tried diet have you tried exercise they'll oblige you to have it as part of a clinical program being administered by a doctor if you're doing it lifestyle reasons and you're going to pharmacy and buying it off label in the grain market that's a very different world.
36:27At the moment, according to the companies, they can't make enough of it. So I think we're getting the situation where we're going to see appeals go out to people, don't use it for lifestyle reasons, because there isn't enough for the diabetics who really need it for life-saving reasons. So there's a really interesting whole set of things how this pans out, which means it's in such a different category from previous things like the Atkins diet. Yeah, Joey, one thing I'd add is remember if we look at the history of diets, which I also think is a fascinating topic on the side, they were largely also based on willpower.
37:03Cut carbs out for a week and you'll binge your carbs on Sunday or cut your alcohol out. And here it's the opposite. You're taking a drug that is actually cutting the desire at the source. And so it's not a consumer-led cutting, it's drug-led cutting, if you will. And that's quite different. We hosted a panel of consumers last week who are on the drug, and the data was mixed on what some people did or didn't do in terms of cutting their alcohol. But when they described other foods like greasy foods, it was actually just that it was unappealing to them. And I think that's the key difference. And then we get into the debate of, well, how long are you staying on this, which is the other big question.
37:42You know, are you staying on this for 12 to 24 months? You're using it to kickstart a more healthy lifestyle. to bring your weight back down. And then you have to try somehow and maintain that afterwards with the help of your physician. But that craving for alcohol will come back. So that's also the key question or on it forever. And that's probably the one biggest difference between any other diet that we've seen where cutting alcohol is recommended. You mentioned that panel with users. What did you learn as far as alcoholic beverage consumption and what they were saying as far as whether they were finding alcoholic beverages appealing or just having a distaste for it at this point?
38:26Yeah, I point to two interesting things. So on the panel, it just so happened that the people we were interviewing, most of them weren't heavy drinkers to begin with. So it wasn't a big change for them to maybe lose that appetite. There was one person who was drinking just as much beer, ironically, and did not give that up, but was cutting down portion sizes for food elsewhere. Another interesting data point was we held a call with a former exec at Walmart, and they had data as well. They found that, Trevor, correct me if I'm wrong, I think it was a 60 % reduction. 60 % of people said they had less appetite for alcohol, but very importantly, it didn't say how much was the reduction in alcohol.
39:10So the only evidence we know for sure is if you have rats in the lab and you make them alcoholic, then they have a reduced appetite for alcohol. So that's the only scientific fact out there. But to keep it, there is an awful lot of anecdotal evidence. There is some reduction in appetite for alcohol. I've seen some numbers that vary between 10 percent and 60 percent, depending on the study. But there certainly is some reduction in appetite for alcohol. but we have no idea do beer drinkers have a bigger reduction than spirits drinkers or wine drinkers so is it a function of the type of alcohol you're drinking i suspect it's much more a function of the type of person who's taking the drugs so coming back to coming back to the point before jessica but who's going to end up taking a zempic and very important as lindeen said who's going to end up staying on a zempic because a lot of consumers don't like the idea of being on a drug forever.
40:06Clinical evidence probably says after two years on the drug, you can come off and keep those good habits in terms of lifestyle and diet and choice. So if we have a bunch of people that try the drug, some never stay on it, some stay on it for two years, but then they go back to their own alcohol habits, then it's even less of something to worry about than what we think at the moment. Yeah, and I would add the one other thing I took away, which maybe is an alcohol pulse specific, but gives you an understanding of, you know, how does it work for some of these consumers is I really came away with the view that it's not a magic pill.
40:40What it does is kickstart weight loss and kickstart better habits such that you can try and reduce portion sizes and understand what that feels like and understand what it's like to be full such that when you come off in two years, you can continue those. But some of the people we had spoken to who came off after one year said those hunger pains come back because the way you lost the weight is by being in a calorie deficit for a year. And all of a sudden, you have to learn how to actually manage your hunger, your appetite when you didn't have to for a year. Bringing this back to alcohol, it shows that actually a lot of those habits can come back afterwards.
41:16Those desires all come back. And this isn't a magic pill that erases our desire for sugar, salt, fat, alcohol altogether. It's a tool that's being used, but it doesn't erase everything. So it sounds like, you know, with a lot of stuff right now, it's a little too soon to tell, but what time period would you both consider long enough for all of us to have a better grasp on the situation? Probably within six months, Jessica, we'll have a lot more numerical evidence, robust numerical evidence about who's actually taking the Zembika, the GLP-1s, what type of person are they, to what extent do they drink or not, and to what extent that changes, and particularly by category.
41:58But what's probably going to be really critical will be the longevity of the change in habits. And so that, I mean, if arguably a Zempic as a weight loss drug is something that started six to 12 months ago, it's probably going to be another year at least before we start to get evidence of how does this change over time and what are the patterns of behavior over time. Is there any early reading right now of what the length of usage is at all? Are you seeing like, is it still in that period where a lot of these, a lot of this usage is just people getting the prescription for the first time? Or are we starting to see some repeats in there?
42:40I would say so far, we're looking at at most 30 % of people are staying on the drug. So there are quite significant side effects here in terms of either constipation or diarrhea, unpleasant side effects that cause people to come off. Some people are just bad at following drug regimes. And for the moment, the GLP-1s for weight loss are injected. So you have to self-inject once a week. Now that may change because there are GLP-1s for diabetes that are in tablet form. So that could well change. There are people who said just be bad because not everybody takes their pills, even things like heart medicine, where you just don't take the pills as often as you should or you stop and then there'll be people who achieve the goals and stop so the evidence you've seen so far say if you end up with 30 40 percent of people for more than one year that would be that's probably what we should be expecting and probably also to consider is who are those people if these are all people who have been prescribed by their physician or weight loss because they are obese or overweight that's going to be very different to you know jessica and zoy what you're describing is your celebrity influence.
43:49I sort of want to just lose five to 10 pounds. This is a quick, easy way, in which case my hunch, and this is just a hunch, is that group of people adherence is probably going to look very different to someone who is taking this for, you know, medical reasons per recommended by a physician. I don't know anybody at the top of the year that probably had weight loss drugs on their bingo card of headwinds for alcoholic beverages. But in your conversations, since this is sort of popped up with leadership at some of the top manufacturers, what are you hearing from them? Is there concern? Are they just feeling it out at this point?
44:28What's the read you're getting? What I'm hearing from my American alcoholic beverage companies is both too soon to tell and we're not really seeing anything yet. Now, who knows? I'm sure they're having plenty of discussions on this internally, but that comes back to Trevor's questions that there are more unknowns than known at the moment. But at the moment, not seeing a huge impact is what they're seeing, at least in alcohol. I think they're all slightly remused, Justin, having talked to a lot of them. They're going, where did this come from? Why are people worried about it? What are GRP ones?
45:05So I think they're a little bit like us, a lot of them. So it tells you something in itself, because given that these firms tend to have large numbers of people worrying about the health implications of alcohol and worrying where legislation might go, and the fact that they're not worried about it tells you something in itself. So clearly, anybody can be prone to complacency. I think where it is, is investors tend to sort of shoot first and ask questions later. So they tend to worry about what's around the corner rather than what's in the here and now. so I'd say in the investment community is much much more worried about this I think that's partly because you know you might be let's say you as an investor you can invest not just in algo companies but in many types of companies you might be thinking of investing a chocolate company and if you're really worried that let's say 10 percent of the population is consuming 50 percent of the candy and they all go on on the on the zembic that could be a big problem for you if you're a chocolate investor.
46:02So then if you're in that mindset already, then you tend to think, oh, what about other things that could be hit? So we already have seen, for example, companies making medical equipment have big impact on their share prices because of anxieties about GLP-1s. And I think what you're seeing is the ripple of that spreading across the financial markets. That's a long-winded way of saying that companies are relatively calm at the moment. It seems to the investment community that's in more of a tizzy. Yeah, Justin, to put this in perspective, we have investors asking us for our best Olympic proof pick for a company to invest in, which is telling you what type of mentality they're in when trying to understand everyone's exposure to this.
46:42Did you get asked what best beyond meat pick you had, like when that was becoming a thing a few years back? No. No, no, no. No. All right. Just curious if there was like a corollary. I suppose probably the best was coming back to, Zoe, you mentioned the Atkins diet. And clearly there are, we know some big beer brands out there make a big thing about being low carbs. And I go all the way back to, I think, Miller Lite. You know, less carbs, no filling. I've forgotten the strap line. Tastes great, less filling. Tastes great, less filling. And when do we see carb side by side in terms of carb levels coming into ads?
47:24So, you know, maybe that persists. I still hear a lot of people say, I drink tequila soda because it's gluten-free. And you go, well, you know, all spirits are gluten-free. Really? So the level of consumer knowledge out there is small. So I can understand why investors are worried or concerned. But I think the probability of something big coming out of this is very low at the moment, based on what we know. Now, we mostly focus on the US beer industry. but you guys have a broader view than we do. So is this more, is concern here mostly concentrated in the States or are other countries worried about it as well?
48:03It's very much US oriented because if you think about the obesity levels, it's 42 % of US adults. In the English speaking world, in the UK, Australia, New Zealand is about 30. In continental Europe, it's 20. And most emerging markets, it's 10 maximum. I think Mexico is the one emerging market that has more of a problem with obesity. So in general, outside of the US, it's on the radar screen, but it's much less significant in terms of the intensity of the dialogue, shall I put it that way. And then maybe the last comparison to make, not only the differences in obesity rates, but the healthcare systems are incredibly different.
48:44And what is the implication for how do you get access to these drugs? And that could be a whole hour conversation in and of itself. And it goes both ways. But, you know, what are consumers attitudes to weight loss or, you know, the latest trends? And I think those are also very different. So main one that Trevor highlighted is, you know, absolutely number one. But there are a lot of other differences under the surface, too. Well, I think this is a fascinating discussion and looking forward to seeing where it goes. Thank you, Trevor and Nadine, for joining us. We really appreciate it. Thank you.
49:18And that's our show for this week. Thanks to Trevor and Nadine for joining us. Thanks to Zoe and Jess for all they do. Thanks to our one-man audio team, Joe. And thanks to all of you for listening. We'll be back next week.
From the publisher
In this special presentation of our sister show, the Brewbound Podcast, Bernstein Autonomous analysts Nadine Sarwat and Trevor Stirling share what they know so far about Ozempic, Wegovy and other diet/diabetes drugs' effect on alcoholic beverage consumption.




